Repository logo
Log In
  1. Home
  2. Unibas
  3. Publications
  4. MAGE-A and NY-ESO-1 expression in cervical cancer : prognostic factors and effects of chemotherapy
 
  • Details

MAGE-A and NY-ESO-1 expression in cervical cancer : prognostic factors and effects of chemotherapy

Date Issued
2008-01-01
Author(s)
Napoletano, Chiara
Bellati, Filippo
Tarquini, Elisabetta
Tomao, Federica
Taurino, Federica
Spagnoli, Giulio  
Rughetti, Aurelia
Muzii, Ludovico
Nuti, Marianna
Benedetti Panici, Pierluigi
DOI
10.1016/j.ajog.2007.05.019
Abstract
OBJECTIVE: The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis. STUDY DESIGN: One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry. RESULTS: MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039). CONCLUSION: Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.
University of Basel

edoc
Open Access Repository University of Basel

  • About edoc
  • About Open Access at the University of Basel
  • edoc Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement